Jennie Young

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.

C. Caldas, E. Provenzano, J. Abraham, 2017, The Lancet. Oncology.

Addressing overtreatment of screen detected DCIS; the LORIS trial.

S. Pinder, M. Wallis, D. Rea, 2015, European journal of cancer.

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.

R. Laing, C. Caldas, E. Provenzano, 2014, The Lancet. Oncology.

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial

S. Pinder, M. Wallis, D. Rea, 2017, Annals of Surgical Oncology.

Abstract P3-17-06: LORIS trial of active monitoring for DCIS: How does the online pathology eligibility review process work?

S. Pinder, A. Francis, A. Hanby, 2017 .